Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Salarius Pharmaceuticals Inc
SLRXCurrent price
0.73 USD
+0.013 USD (+1.85%)
Last closed
0.72 USD
Company
www.salariuspharma.com
ISIN
US79400X4043
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
1 530 585 USD
Yield for 12 month
-81.07 %
1Y
3Y
5Y
10Y
15Y
SLRX
Salarius Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is based in Houston, Texas. Address: 2450 Holcombe Blvd., Houston, TX, United States, 77021
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
26.00 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
–
Current Year
–
Last Year
-10 051 USD
Current Quarter
–
Last Quarter
–
Key Figures SLRX
1 year
3 years
5 years
10 years
EBITDA
-5 729 892 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-74.59 %
PEG Ratio
–
Return On Equity TTM
-164.02 %
Wall Street Target Price
26.00 USD
Revenue TTM
–
Book Value
1.05 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-100.00 %
Dividend Yield
–
Gross Profit TTM
-15 836 828 USD
Earnings per share
-5.79 USD
Diluted Eps TTM
-5.79 USD
Most Recent Quarter
IV 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics SLRX
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History SLRX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
1:8
Payout Ratio TTM
–
Last Split Date
17.06.2024
Stock Valuation SLRX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
0.14
Price Sales TTM
18.12
Enterprise Value EBITDA
1.52
Price Book MRQ
1.01
Financials SLRX
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators SLRX
For 52 weeks
0.45 USD
4.50 USD
50 Day MA
0.97 USD
Shares Short Prior Month
40 435
200 Day MA
1.61 USD
Short Ratio
0.38
Shares Short
138 176
Short Percent
8.05 %
BeatStart